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========

Introduction {#Sec2}
------------

The neutrophil to lymphocyte ratio (NLR) has gained interest as an independent predictor of survival in patients with various clinical conditions, ranging from oncological to cardiovascular diseases. NLR has also been reported to predict bacteremia better than other infection markers \[[@CR1]\], and an NLR \> 7 was reportedly an independent marker of mortality in patients with bacteremia \[[@CR2]\].

Gastrointestinal perforation (GIP) is a life-threatening disease with a high mortality rate; GIP often leads to shock and usually requires active rescue in the intensive care unit (ICU) and emergency laparotomy \[[@CR3]\]. No previous study has reported an association between inflammation-based prognostic scores and outcomes in patients with GIP.

We hypothesized that NLR measured at the time of admission to the ICU may better predict in-hospital mortality in patients with GIP, as compared with other inflammation-based prognostic scores. To test this hypothesis, we compared the prognostic value of various inflammation-based prognostic scores in patients with GIP.

Methods {#Sec3}
-------

We conducted a single-center retrospective study in a 16-bed ICU. The study protocol was approved by the Ethics Committee of Osaka Medical College (Osaka, Japan). A total of 40 patients diagnosed with GIP, who underwent surgery and were treated in the ICU of Osaka Medical College Hospital between January 2014 and June 2016, were retrospectively enrolled. Of these, 32 patients were evaluated, excluding those who were aged 18 years or younger; who were pregnant; who had immunosuppressive disease (e.g., HIV), or were undergoing immunosuppressive therapy (e.g., chemotherapy, chronic use of steroids, autoimmune disease treatment) within 1 month of the study; and who had cardiac arrest at the time of ICU admission. Individual patient consent was not obtained since all data used in this study were acquired retrospectively from the laboratory information system without any additional blood sampling or laboratory analysis. The main outcome measure was in-hospital mortality. The following demographic and clinical data were collected: age, sex, comorbidities (cancer, coronary artery disease, diabetes mellitus, hypertension, and renal disease), Sequential Organ Failure Assessment-Glasgow Coma Scale (SOFA-GCS) score at ICU day 1, length of hospital stay, and in-hospital mortality. Since our study population included intubated patients under sedation with propofol and/or dexmedetomidine at ICU admission, we excluded the GCS item from the SOFA score. Blood samples were obtained upon ICU admission for measurements of CRP, albumin, white blood cell count, neutrophil count, lymphocyte count, and platelet count. The GPS, NLR, PLR, PI, and PNI were obtained as shown in Table [1](#Tab1){ref-type="table"}.Table 1Inflammation-based prognostic scoresScoring systemsScoreGlasgow Prognostic Score CRP (≤ 10 mg l^−1^) and albumin (≥ 35 g l^−1^)0 CRP (≤ 10 mg l^−1^) and albumin (\< 35 g l^−1^)1 CRP (\> 10 mg l^−1^) and albumin (≥ 35 g l^−1^)1 CRP **(\>** 10 mg l^−1^) and albumin (\< 35 g l^−1^)2Neutrophil to lymphocyte ratio Neutrophil count: lymphocyte countPlt to lymphocyte ratio Plt count: lymphocyte countPrognostic Index CRP (≤ 10 mg l^−1^) and white blood cell count (≤ 11 × 10^9^ l^−1^)0 CRP (≤ 10 mg l^−1^) and white blood cell count (\> 11 × 10^9^ l^−1^)1 CRP (\> 10 mg l^−1^) and white blood cell count (≤ 11 × 10^9^ l^−1^)1 CRP (\>10 mg l^−1^) and white blood cell count (\>11 × 10^9^ l^−1^)2Prognostic Nutritional Index Albumin (g l^−1^) + 5 × total lymphocyte count 10^9^ l^−1^*CRP* C-reactive protein, *Plt* platelet

Descriptive analysis was performed for all variables. Continuous variables were expressed as median (interquartile range), and categorical variables as counts (percentage). Patient characteristics were compared between survivors and non-survivors using Fischer's exact test. Univariate analysis and multivariate analysis (Cox proportional hazards model) were used to examine associations between patient characteristics and prognostic factors. Analyses using Cox proportional hazards models were performed by forward selection of variables which were found to be significant by univariate analysis and inflammation-based prognostic scores. Receiver operating characteristics (ROC) curves were generated for variables which were significant in the multivariate analysis, and areas under the curve (AUCs), cutoff values, sensitivities, specificities, and predictive values were calculated. Using these cutoff values, overall survival rates (in-hospital mortality) were calculated with the Kaplan--Meier method, and differences in survival rates between groups were compared by the log-rank test. A *P* value \< 0.05 was considered statistically significant. All statistical analyses were performed using the BellCurve for Excel software package v.2.0 (Social Survey Research Information Co., Ltd., Tokyo, Japan).

Results {#Sec4}
-------

Baseline characteristics of the patients are shown in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Twenty-four (75%) patients were survivors (perforation in the colon, 16; small intestine, 6; stomach, 1; appendix, 1), and 8 (25%) were non-survivors (colon, 4; small intestine, 4). The median age was 74 (range, 65.5--79) years for survivors and 66.5 (range, 64.5--73) years for non-survivors. Among survivors, 10 (41.7%) patients were males and 14 (58.3%) were females, and among non-survivors, 4 (50%) were males and 4 (50%) were females.Table 2Patient demographicsAll patientsUnivariate analysisSurvivorsNon-survivors*P* valueVariables(*n* = 24)(*n* = 8)Age, year74 (65.5--79)66.5 (64.5--73)0.58Female14 (58.3)4 (50)0.62Male10 (41.7)4 (50)Cancer16 (67)6 (75)0.69CAD10Diabetes40Hypertension80Renal disease1 (4)3 (38)0.039Observation period36 (24--46.5)20.5 (13.8--25.8)0.0069Albumin (g l^−1^)19 (14.8--24)23 (13.8--28.3)0.406CRP (mg l^−1^)11.5 (8.3--18)9.1 (5.4--15)0.809WBC (× 10^9^ l^−1^)6.3 (3.6--8.4)4.8 (3.8--6.8)0.552Neutrophil count (× 10^9^ l^−1^)5.3 (2.9--7.2)3.8 (3.2--4.9)0.454Lymphocyte count (× 10^9^ l^−1^)0.49 (0.36--0.78)0.31 (0.28--0.37)0.064Plt count (× 10^4^ mm^−3^)17.3 (15.2--23.2)21.1 (8.0--29)0.484*CAD* coronary artery disease, *CRP* C-reactive protein, *WBC* white blood cell, *Plt* platelet Table 3Inflammation-based prognostic scoresAll patientsUnivariate analysisSurvivorsNon-survivors*P* valueVariables(*n* = 24)(*n* = 8)SOFA-GCS score at ICU admission3 (2--4.25)6.5 (4.8--8.3)0.0087GPS (0/1/2)(0/8/16)(0/5/3)0.161NLR8.7 (6.4--14.9)13.7 (7.7--15.6)0.432PLR390.2 (279.8--688.5)596.2 (274.8--783.8)0.057PI (0/1/2)(8/12/4)(4/4/0)0.262PNI20.6 (17.4--25.8)24.3 (15.4--29.8)0.611*SOFA* Sequential Organ Failure Assessment, *GCS* Glasgow Coma Scale, *ICU* intensive care unit, *GPS* Glasgow Prognostic Score, *NLR* neutrophil to lymphocyte ratio, *PLR* platelet to lymphocyte ratio, *PI* Prognostic Index, *PNI* Prognostic Nutritional Index

Multivariate Cox proportional hazards models revealed NLR (HR 1.257, 95% CI 1.035--1.527, *P* = 0.021) and PLR (HR 1.004, 95% CI 1.001--1.007, *P* = 0.016) to be independently associated with in-hospital mortality (Table [4](#Tab4){ref-type="table"}). Cutoff values for mortality obtained from ROC analysis (Fig. [1](#Fig1){ref-type="fig"}) were 13.28 (sensitivity, 62.5%; specificity, 66.7%; area under the curve (AUC), 0.57; 95% CI, 0.31--0.83; *P* = 0.607) for NLR and 590.44 (sensitivity, 62.5%; specificity, 66.7%; AUC, 0.58; 95% CI, 0.33--0.84; *P* = 0.521) for PLR (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). AUC analyses revealed SOFA-GCS (0.73) to be superior to NLR (0.57) and PLR (0.58) for predicting mortality (Table [6](#Tab6){ref-type="table"}). A high SOFA-GCS score was associated with reduced overall survival (*P* \< 0.05) (Fig. [2](#Fig2){ref-type="fig"}).Table 4Predictors of mortality by multivariate analysisPredictorsHazard ratio95% CI*P* valueSOFA-GCS score1.7091.108--2.6370.015NLR1.2571.035--1.5270.021PLR1.0041.001--1.0070.016Renal disease1.2380.13--11.8210.853*SOFA* Sequential Organ Failure Assessment, *GCS* Glasgow Coma Scale, *NLR* neutrophil to lymphocyte ratio, *PLR* platelet to lymphocyte ratio Fig. 1Receiver operating characteristic curves of inflammation-based prognostic scores for predicting mortality. **a** NLR. **b** PLR. **c** SOFA-GCS Table 5Performance parameters for predictors of mortalityPredictorsCutoff valueSensitivity (%)Specificity (%)PPV (%)NPV (%)SOFA-GCS67587.566.791.3NLR13.2862.566.738.584.2PLR590.4462.566.738.584.2*PPV* positive predictive value, *NPV* negative predictive value, *SOFA* Sequential Organ Failure Assessment, *GCS* Glasgow Coma Scale, *NLR* neutrophil to lymphocyte ratio, *PLR* platelet to lymphocyte ratio Table 6Comparison of AUC between predictorsPredictorsAUC95% CI*P* valueSOFA-GCS0.730.44--1.020.112NLR0.570.31--0.830.607PLR0.580.33--0.840.521*AUC* area under the curve, *SOFA* Sequential Organ Failure Assessment, *GCS* Glasgow Coma Scale, *NLR* neutrophil to lymphocyte ratio, *PLR* platelet to lymphocyte ratio Fig. 2Kaplan-Meier survival curves for inflammation-based prognostic scores. **a** NLR. **b** PLR. **c** SOFA-GCS

Discussion {#Sec5}
----------

NLR and PLR were found to be superior to other inflammation-based prognostic scores in predicting the mortality of patients with GIP. NLR and PLR are based primarily on the physiological link between neutrophilia and lymphopenia with systemic inflammation. Jilma et al. \[[@CR4]\] studied changes in white blood cell types after inflammation and reported a 300% increase in circulating neutrophils, 96% decrease in monocytes, and 85% decrease in lymphocytes 4 to 6 h after inflammation. Below, we discuss the literature surrounding NLR and the prognostic capabilities of NLR for GIP.

Growing evidence suggests the usefulness of NLR in the prediction of survival in various contexts, such as lung cancer, colorectal cancer, orthotopic liver transplantation for primary hepatocellular carcinoma, postoperative coronary artery bypass grafting, chronic heart failure, pulmonary emboli, and acute pancreatitis \[[@CR1], [@CR5], [@CR6]\]. Moreover, NLR was a more sensitive parameter than increased white blood cell count in patients with suspected appendicitis \[[@CR7]\]. These data suggest the importance of NLR in multiple patient populations.

In the present study, NLR and PLR had a positive predictive value of 38.5% and a negative predictive value of 84.2%, suggesting that NLR and PLR may be more useful for ruling out mortality, rather than predicting it. NLR and PLR can be obtained easily, cheaply, and rapidly and can provide relevant information for necessary interventions within the first few hours of hospital admission. As discussed earlier, studies have shown that NLR predicts bacteremia better than other infection markers \[[@CR1]\] and an NLR \> 7 was reportedly an independent predictor of mortality in patients with bacteremia \[[@CR2]\]. In another study, the initial NLR measured at ED admission was independently associated with 28-day mortality in patients with severe sepsis and septic shock \[[@CR8]\]. However, these previous studies did not assess associations between inflammation-based prognostic scores, including the GPS, NLR, PLR, PNI, and PI, and mortality in patients with GIP. Our results are informative in this respect.

This study has a potential limitation. Given the retrospective, single-center design of the study and small cohort, multivariate analysis may be difficult to apply. A large-scale prospective validation study will be needed to confirm our results.

Conclusion {#Sec6}
----------

NLR and PLR were superior to other inflammation-based prognostic scores in predicting the mortality of patients with GIP.
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